These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 34232546)

  • 1. The Prognostic Impact of KRAS G12C Mutation in Patients with Metastatic Colorectal Cancer: A Multicenter Retrospective Observational Study.
    Chida K; Kotani D; Masuishi T; Kawakami T; Kawamoto Y; Kato K; Fushiki K; Sawada K; Kumanishi R; Shirasu H; Matsubara Y; Yuki S; Komatsu Y; Yamazaki K; Yoshino T
    Oncologist; 2021 Oct; 26(10):845-853. PubMed ID: 34232546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-World Study of Characteristics and Treatment Outcomes Among Patients with KRAS p.G12C-Mutated or Other KRAS Mutated Metastatic Colorectal Cancer.
    Fakih M; Tu H; Hsu H; Aggarwal S; Chan E; Rehn M; Chia V; Kopetz S
    Oncologist; 2022 Aug; 27(8):663-674. PubMed ID: 35472176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group.
    Modest DP; Ricard I; Heinemann V; Hegewisch-Becker S; Schmiegel W; Porschen R; Stintzing S; Graeven U; Arnold D; von Weikersthal LF; Giessen-Jung C; Stahler A; Schmoll HJ; Jung A; Kirchner T; Tannapfel A; Reinacher-Schick A
    Ann Oncol; 2016 Sep; 27(9):1746-53. PubMed ID: 27358379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KRAS G12C Metastatic Colorectal Cancer: Specific Features of a New Emerging Target Population.
    Schirripa M; Nappo F; Cremolini C; Salvatore L; Rossini D; Bensi M; Businello G; Pietrantonio F; Randon G; Fucà G; Boccaccino A; Bergamo F; Lonardi S; Dei Tos AP; Fassan M; Loupakis F
    Clin Colorectal Cancer; 2020 Sep; 19(3):219-225. PubMed ID: 32605718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive Clinical and Molecular Characterization of
    Henry JT; Coker O; Chowdhury S; Shen JP; Morris VK; Dasari A; Raghav K; Nusrat M; Kee B; Parseghian C; Pant S; Jeyakumar N; Zhu L; Nishioka Y; Fogelman D; Wolff RA; Hong D; Overman MJ; Vauthey J; Kopetz S; Johnson B
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34250391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retrospective Comparative Analysis of KRAS G12C
    Giampieri R; Lupi A; Ziranu P; Bittoni A; Pretta A; Pecci F; Persano M; Giglio E; Copparoni C; Crocetti S; Mandolesi A; Faa G; Coni P; Scartozzi M; Berardi R
    Front Oncol; 2021; 11():736104. PubMed ID: 34660299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Multicenter Retrospective Chart Review of Clinical Outcomes Among Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer.
    Iams WT; Balbach ML; Phillips S; Sacher A; Bestvina C; Velcheti V; Wang X; Marmarelis ME; Sethakorn N; Leal T; Sackstein PE; Kim C; Robinson MA; Mehta K; Hsu R; Nieva J; Patil T; Camidge DR
    Clin Lung Cancer; 2023 May; 24(3):228-234. PubMed ID: 36841727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association Between Specific Mutations in KRAS Codon 12 and Colorectal Liver Metastasis.
    Margonis GA; Kim Y; Spolverato G; Ejaz A; Gupta R; Cosgrove D; Anders R; Karagkounis G; Choti MA; Pawlik TM
    JAMA Surg; 2015 Aug; 150(8):722-9. PubMed ID: 26038887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Impact of PI3K/BRAF Mutations in RAS Wild Metastatic Colorectal Cancer: Meta-analysis Results.
    Mohamed A; Twardy B; AbdAllah N; Akhras A; Ismail H; Zordok M; Schrapp K; Attumi T; Tesfaye A; El-Rayes B
    J Gastrointest Cancer; 2019 Jun; 50(2):269-275. PubMed ID: 29388061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KRAS Exon 2 Mutations as Prognostic Indicators in Advanced Colorectal Cancer in Clinical Practice: A Mono-Institutional Study.
    Dadduzio V; Basso M; Rossi S; Cenci T; Capodimonti S; Strippoli A; Orlandi A; Cerchiaro E; Schinzari G; Cassano A; Martini M; Barone C
    Mol Diagn Ther; 2016 Feb; 20(1):65-74. PubMed ID: 26610798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KRAS mutations are associated with inferior clinical outcome in patients with metastatic colorectal cancer, but are not predictive for benefit with cediranib.
    Smith JC; Brooks L; Hoff PM; McWalter G; Dearden S; Morgan SR; Wilson D; Robertson JD; Jürgensmeier JM
    Eur J Cancer; 2013 Jul; 49(10):2424-32. PubMed ID: 23510802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrating
    Ntavatzikos A; Spathis A; Patapis P; Machairas N; Peros G; Konstantoudakis S; Leventakou D; Panayiotides IG; Karakitsos P; Koumarianou A
    World J Gastroenterol; 2017 Aug; 23(32):5913-5924. PubMed ID: 28932083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic values of EGFR expression and KRAS mutation in patients with synchronous or metachronous metastatic colorectal cancer.
    Huang CW; Tsai HL; Chen YT; Huang CM; Ma CJ; Lu CY; Kuo CH; Wu DC; Chai CY; Wang JY
    BMC Cancer; 2013 Dec; 13():599. PubMed ID: 24330663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic and Predictive Impact of Primary Tumor Sidedness for Previously Untreated Advanced Colorectal Cancer.
    Yin J; Cohen R; Jin Z; Liu H; Pederson L; Adams R; Grothey A; Maughan TS; Venook A; Van Cutsem E; Punt C; Koopman M; Falcone A; Tebbutt NC; Seymour MT; Bokemeyer C; Rubio ED; Kaplan R; Heinemann V; Chibaudel B; Yoshino T; Zalcberg J; Andre T; De Gramont A; Shi Q; Lenz HJ
    J Natl Cancer Inst; 2021 Nov; 113(12):1705-1713. PubMed ID: 34061178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression.
    Obermannová R; Van Cutsem E; Yoshino T; Bodoky G; Prausová J; Garcia-Carbonero R; Ciuleanu T; Garcia Alfonso P; Portnoy D; Cohn A; Yamazaki K; Clingan P; Lonardi S; Kim TW; Yang L; Nasroulah F; Tabernero J
    Ann Oncol; 2016 Nov; 27(11):2082-2090. PubMed ID: 27573561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie).
    Huemer F; Thaler J; Piringer G; Hackl H; Pleyer L; Hufnagl C; Weiss L; Greil R
    BMC Cancer; 2018 Jan; 18(1):11. PubMed ID: 29298682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KRAS p.G13D mutation and codon 12 mutations are not created equal in predicting clinical outcomes of cetuximab in metastatic colorectal cancer: a systematic review and meta-analysis.
    Mao C; Huang YF; Yang ZY; Zheng DY; Chen JZ; Tang JL
    Cancer; 2013 Feb; 119(4):714-21. PubMed ID: 22972628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Frequency of Specific KRAS Mutations, and Their Impact on Treatment Choice and Survival, in Patients With Metastatic Colorectal Cancer.
    Fernández Montes A; Alonso Orduña V; Asensio Martínez E; Rodríguez Salas N; Torres E; Cacho Lavín D; Rodríguez Alonso RM; Falcó E; Oliva JC; Cirera L; García Gómez J; Pericay C
    Oncologist; 2023 Oct; 28(10):e902-e909. PubMed ID: 37141400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RAC1b overexpression correlates with poor prognosis in KRAS/BRAF WT metastatic colorectal cancer patients treated with first-line FOLFOX/XELOX chemotherapy.
    Alonso-Espinaco V; Cuatrecasas M; Alonso V; Escudero P; Marmol M; Horndler C; Ortego J; Gallego R; Codony-Servat J; Garcia-Albeniz X; Jares P; Castells A; Lozano JJ; Rosell R; Maurel J
    Eur J Cancer; 2014 Jul; 50(11):1973-81. PubMed ID: 24833563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study.
    Personeni N; Rimassa L; Verusio C; Barni S; Rubino L; Bozzarelli S; Villa E; Carnaghi C; Tronconi MC; Gerardi C; Galli F; Floriani I; Destro A; Raschioni C; Labianca R; Santoro A
    Clin Colorectal Cancer; 2015 Sep; 14(3):162-9. PubMed ID: 25861836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.